InCellDx, Inc.

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

• BBBrian BrothenExecutive Officer
• MGMarc GrodmanDirector
• LGLowell GrumanExecutive Officer
• EHEric HassExecutive Officer
• LLLinda LawDirector
• BPBruce PattersonDirector · Executive Officer
• CPCarol Penfold-PattersonDirector · Executive Officer
• TTThaddeus TaubeDirector
• CTCharles ToddDirector
• CWChris WheelerExecutive Officer

• 06 Jan 2026Methods and Systems for Predicting Whether a Subject Has a Cervical Intraepithelial Neoplasia (CIN) Lesion from a Suspension Sample of Cervical Cellsgranted
• 26 Jun 2025Methods of Treating a Subject for Post-Treatment Lyme Disease (PTLD) and Compositions for Use in the Sameapplication
• 26 Jun 2025Methods of Treating a Subject for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Compositions for Use in The Sameapplication
• 13 May 2025Methods of Assaying Neoplastic and Neoplasia-Related Cells and Uses Thereofgranted
• 27 Mar 2025Methods of Treating a Subject for Long-Haul COVID-19, and Compositions for Use in the Sameapplication
• 18 Feb 2025Methods Of Assigning A Covid Pathological Type Based On A Cytokine/chemokine Panelgranted
• 21 May 2024Methods of Assessing Cellular Breast Samples and Compositions for Use in Practicing the Samegranted
• 09 Apr 2024Method Of Treating Hypercytokinemia By Administering The CCR5/CCL5 (rantes) Interaction Inhibitor Maravirocgranted
• 18 Jan 2024Methods of Assigning a COVID Pathological Type and Compositions for Practicing the Same, and Methods of Treating a Subject for Chronic COVID-19application
• 14 Sept 2023HPV E6, E7 MRNA Assay and Methods of Use Thereofapplication
• 15 Aug 2023Methods of Assaying Neoplastic and Neoplasia-Related Cells and Uses Thereofgranted
• 18 Apr 2023Method Of Treating SARS-COV-2-ASSOCIATED Hypercytokinemia By Administering A Human Monoclonal Antibody (PRO-140) That Inhibits CCR5/CCL5 Binding Interactionsgranted

• 07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
• 30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
• 30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
• 29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
• 26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
• 26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.